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Interpretation of diffusion MRI in the living brain requires validation against gold standard
histological measures. We compared diffusion values of the nigrostriatal tract to PET and
histological results in non-human primates (NHPs) with varying degrees of unilateral nigros-
triatal injury induced by MPTP, a toxin selective for dopaminergic neurons.
Methods
Sixteen NHPs had MRI and PET scans of three different presynaptic radioligands and
blinded video-based motor ratings before and after unilateral carotid artery infusion of vari-
able doses of MPTP. Diffusion measures of connections between midbrain and striatum
were calculated. Then animals were euthanized to quantify striatal dopamine concentration,
stereologic measures of striatal tyrosine hydroxylase (TH) immunostained fiber density and
unbiased stereologic counts of TH stained nigral cells.
Results
Diffusion measures correlated with MPTP dose, nigral TH-positive cell bodies and striatal
TH-positive fiber density but did not correlate with in vitro nigrostriatal terminal field mea-
sures or in vivo PET measures of striatal uptake of presynaptic markers. Once nigral TH cell
count loss exceeded 50% the stereologic terminal field measures reached a near zero floor
effect but the diffusion measures continued to correlate with nigral cell counts.
Conclusion
Diffusion measures in the nigrostriatal tract correlate with nigral dopamine neurons and
striatal fiber density, but have the same relationship to terminal field measures as a previous
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report of striatal PET measures of presynaptic neurons. These diffusion measures have the
potential to act as non-invasive index of the severity of nigrostriatal injury. Diffusion imaging
of the nigrostriatal tract could potentially have diagnostic value in humans with Parkinson
disease or related disorders.
Introduction
Diffusion tensor imaging (DTI) and diffusion tensor tractography (DTT) have been estab-
lished as sensitive and valuable methods for probing microscopic changes in brain tissue in
health and disease states. Numerous applications for these methods have been demonstrated
in both clinical and research settings [1]. However, the interpretation of these methods
remains uncertain, since the microscopic changes that underlie the observed macroscopic DTI
changes often remain unclear [2]. In particular, measuring quantitative change in DTI mea-
sures is challenging in areas of brain with many crossing fibers.
The potential challenge posed by crossing or diverging/converging fibers may limit applica-
tion of these methods for quantification of the nigrostriatal pathway. This dopaminergic (DA)
pathway degenerates in people with Parkinson disease (PD) which causes the initial motor
manifestations of the disease. Objective measures of the integrity of this pathway could be use-
ful for testing new therapies that may slow PD progression. Molecular imaging methods have
focused on measurements of striatal uptake of various radioligands targeting presynaptic func-
tion such as [18F]-6-fluorodopa (FD) (which primarily reflects presynaptic decarboxylase
activity and subsequent storage), [11C]dihydrotetrabenazine (DTBZ) (which has specificity for
vesicular monamine transporter type 2 [VMAT2]) and a variety of membranous presynaptic
dopamine transporter (DAT) radioligands including [11C]carbomethoxy-3beta-(4-flurophe-
nyl)tropane (CFT) [3, 4]. Striatal uptake of these various radioligands reflects severity of
nigrostriatal injury but only when less than 50% of nigral DA neuronal cells bodies are lost; At
that point, these terminal field biomarkers have reached a nadir and no longer reflect increas-
ing nigrostriatal injury, whereas nigral cell body injury fully reflects the subsequent severity of
parkinsonism[3–5]. Thus, a measure of nigrostriatal fiber integrity could provide an alterna-
tive measure of this dopaminergic system.
In the current study we used a non-human primate (NHP) animal model with varying
degrees of nigrostriatal injury produced by a single internal carotid infusion of graded doses of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), toxin selective for dopaminergic neu-
rons. This model permits cross modality comparisons of dopaminergic biomarkers using in
vivo MRI DTI measures with in vivo PET measures, and behavioral ratings of motor parkin-
sonism. In vitro measures include counts of nigral cell bodies of dopaminergic neurons in the
substantia nigra and striatal DA fiber length density, which reflects axonal integrity [6]. Addi-
tionally, terminal field measures of these neurons in the striatum include striatal dopamine
concentration, immunohistochemical measures of dopamine transporter (DAT) varicosities,
and terminal arbor densities [5, 6]. Table 1 summarizes the multiple measures investigated in
this study and their association with either the nigrostriatal track or the terminal fields of the
striatum. Our hypothesis in the current study was that DTI and DTT measures would correlate
with severity of nigrostriatal injury defined by loss of in vitro measures of nigral dopaminergic
(DA) neurons or striatal fiber length density but not provide comparable information with
either in vivo PET or in vitro histological terminal field measures in striatum.
Diffusion tensor imaging measures of nigrostriatal neurons
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Materials and methods
Monkey husbandry
Sixteen male macaque nemestrina (mean age = 5.4 +/- 1.0) were housed in the nonhuman pri-
mate facility of Washington University of St. Louis (WU), and were studied according to
requirements of the NIH, and after approval of the Institutional Animal Care and Use commit-
tee (IACUC) at WU. The protocol numbers have been 20170100, 20140128, 20110161
(renewed every three years and the last approval date was July 6, 2017). All animals were
obtained from licensed nonhuman primates facilities with the assistance and oversight of the
Division of Comparative Medicine at Washington University. All procedures were designed to
conform to suggestions of the 2006 Weatherall Report “The use of non-human primates in
research” with steps taken to ameliorate subject suffering in accordance with the requirements
of the NIH. Animals were maintained in facilities with 12 hour dark light cycles, were given
access to food and water ad libitum, and provided with a variety of psychologically enriching
tasks such as watching movies or playing with appropriate toys to avoid effects of sensory dep-
rivation. The NHPs were monitored daily by the researchers, animal care staff and a veterinar-
ian to check their general health and welfare. Each animal had baseline training and scans. All
procedures including scans and administration of MPTP were done under anesthesia.
Humane endpoints were pre-defined in this protocol; however, death was not an endpoint of
this study, and none of the animals in this report were euthanized prior to the planned time
point. After MPTP lesioning, we continued behavioral observation and imaging data collec-
tion for 2 months after which we performed euthanasia to permit analysis of in vitro measures
to compare with in vivo measures. After the last scan, each animal was euthanized with pento-
barbital at least 150 mg/kg IV, the brain was rapidly removed and tissue was prepared, stained,
and counted [7].
Lesion methods
Monkeys were scanned with MRI and PET prior to lesioning. After overnight fasting with
access to water up to two hours before the procedure, animals were initially sedated with keta-
mine 10–20 mg/kg i.m. and given gluycopyrrolate to reduce secretions. At that point, animals
were intubated with a soft cuff endotracheal tube and then anesthesia was maintained with Iso-
flurane inhalation (1–3%) with oxygen; thus there was no need for restraints. MPTP (Sigma,
St. Louis, MO; 0.1 mg/ml in normal saline) with doses varying from 0 to 0.31 mg/kg was
infused no faster than 1 ml per minute into the right internal carotid artery under angio-
graphic control when the animals were anesthetized, as described elsewhere [7, 8]. MPTP dose
was varied to induce different degrees of neuronal injury. Angiograms before and after the
Table 1. Summary of nigrostriatal measures.
Substantia Nigra and Nigrostriatal tract Terminal Fields in the Striatum
Ex vivo/Stereology Nigral cell count
Striatal fiber length density
Striatal Dopamine
Striatal DAT Varicosity Density
Striatal Terminal Arbor Density
Radioligands/PET - - [18F]-6-fluorodopa (FD)
[11C]dihydrotetrabenazine (DTBZ)
[11C]carbomethoxy-3beta-(4-flurophenyl)tropane (CFT)
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infusion documented maintenance of proper catheter position and good distal blood flow.
Proper safety procedures were followed for handling MPTP and all contaminated tissues and
waste products [8]. MPTP was given to only one side of the brain to produce contralateral par-
kinsonism which permitted all animals to care for themselves (defined as able to eat and drink
independently, move around the housing facility without difficulty without apparent discom-
fort) and received no dopaminergic drugs at any time. PET and MRI scans were repeated at a
minimum of 4 weeks after treatment with MPTP to allow for resolution of acute effects [6].
Behavioral evaluations of parkinsonism
Each animal was videotaped several times during the period 3–5 months before and up to 2
months after MPTP treatment for behavioral ratings. The videos were scored by the same
observer who was blinded to the MPTP dose. The ratings focused on parkinsonian features
(bradykinesia, tremor, and flexed posturing) using a previously validated scale (0 to 18 per
side) that was developed specifically for non-human primate studies [8, 9]. Further details of
behavioral ratings are provided in prior publications [6].
PET scans
Three PET radiotracers were used to assess presynaptic dopaminergic nigrostriatal neurons:
FD, DTBZ and CFT. Animals were anesthetized [8] and scanned on a Siemens Microsystems
(Knoxville, TN) MicroPET Focus 220 scanner [10]. A transmission scan was followed by IV
injection of 7.7–10.4mCi of DTBZ, 7.7–10.4mCi of CFT, or 3-10mCi of FD. PET data were
collected for 120 minutes for all tracers. There was a 3 hour gap between each radiopharma-
ceutical injection, with FD being the last in accordance with the longer half-life of [18F] (110
min versus 20 min for [11C]). No correction of intra-scan motion was needed since the anes-
thetized animal’s head was immobilized over the duration of each scan following radiophar-
maceutical injection. PET data were acquired over multiple days, as previously described [3].
The first acquired PET scan defined a baseline. To assess interval change, PET images acquired
on subsequent days were co-registered to the baseline.
PET analysis
All volume of interest (VOI) analysis was done by investigators blinded to the clinical status of
the monkeys. Caudate, putamen and a reference occipital region were manually traced as
VOIs on structural T1w MRI images of each monkey. For each monkey, the structural image
was registered to the target PET scan using a previously described technique [11]; hence, all
structural and PET emission data were mutually in register. Tissue time-activity curves were
evaluated in the traced VOIs [11]. To reduce volume averaging with neighboring regions the
VOIs were eroded to include only voxels with at least 90% of the maximal counts within that
VOI. After extracting the tissue activity curves, we calculated the influx constant (KOCC) for
FD data [12], and the non-displaceable binding potential (BPND) for CFT and DTBZ [13].
These PET data have been reported previously[3].
MRI methods
The MRI obtained prior to lesioning was not used in this study. MRI scanning on each NHP
was performed under anesthesia at least 4 weeks after MPTP (mean = 59 days, range 30–123
days) to allow for resolution of any acute effects after MPTP treatment. All scans were done on
a Siemens Trio 3T scanner with a knee coil. Anatomical scans were obtained using
T1-weighted (T1w) MPRAGE sequence (voxel size 0.8 mm3; TR/TE/TI 1900/3.5/1000 ms;
Diffusion tensor imaging measures of nigrostriatal neurons
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IPAT 2) and T2-weighted (T2w) SPACE sequence (voxel size 0.8 mm3; TR/TE 3200/243 ms;
IPAT 2). Diffusion imaging was performed using a spin-echo EPI sequence (voxel size
1.1 mm3; TR/TE 6200/74; IPAT 2) with 60 directional vectors with a b value of 1000 s/mm2
and 6 baseline images with b value of 0. The diffusion scan was repeated 8 times to improve
signal to noise.
All individual diffusion images were internally registered to the b0 image, which in turn
was registered to the T2w image with stretch and shear enabled (12-parameter affine trans-
form) to partially compensate for echo planar imaging (EPI) distortion. The T2w images
then were registered to the individual T1w images using a multimodal registration with vec-
tor gradient metric maximization [14]. Finally, the T1w images were registered to an atlas
representative macaque nemestrina target produced by mutual co-registration of the
MPRAGE images from 10 of the monkeys prior to lesioning. Algebraic composition of trans-
forms enabled resampling of any data type in register with any other. Thus, regions of inter-
est (ROI) generated on anatomical images could be applied in register with the DTI data to
permit DTI parameter measurement and tracking. These techniques were implemented as
described in humans [14]. The diffusion tensor in each voxel was computed using the FSL
diffusion toolbox [15] and derived measures of mean diffusivity (MD), axial diffusivity (AD),
radial diffusivity (RD), and fractional anisotropy (FA) were computed in each voxel of the
brain.
DTI tracking
DTI probabilistic tracking was performed using the FSL package (Oxford, UK) [15, 16] to
identify the nigrostriatal tracts. An expert macaque anatomist (MK) placed ROIs in the bilat-
eral substantia nigra (SN) and the putamen (PUT) of the macaque atlas. These ROIs were
transformed back into each monkey’s individual DTI space for the purpose of DTI parameter
sampling and tracking. Each ROI position was inspected for accuracy by an experienced oper-
ator and a neuroradiologist (JR, JSS). ROI positioning was minimally adjusted for each indi-
vidual macaque based on visual inspection. DTI tracking was performed separately on the left
and on the right side of each monkey brain between the SN and PUT. Sample track volumes in
a single monkey are demonstrated in Fig 1. Following tracking between the two regions an
optimal tract volume was created by selecting a threshold of 0.03. In the final step of the DTI
processing, DTI parameter values were sampled within the track volume and within each of
the ROIs.
Ex vivo methods
Striatal dopamine was measured using high-performance liquid chromatography (HPLC)
with electrochemical detection [7, 17] and expressed as nanograms per gram of brain tissue.
Unbiased stereological counts of nigrostriatal neurons were done on tyrosine hydroxylase
(TH) immunostained midbrain slices [7]. Only TH positive neurons were counted. There
were no TH negative nigral cells as judged by morphology with cresyl violet counter staining.
Striatal fiber length density, immunohistochemical measures of dopamine transporter (DAT)
varicosities and terminal arbor densities were measured with stereologic methods, as previ-
ously described[5]. These in vitro data have been reported previously[5, 6].
Statistical methods
For all measurements, we calculated a ratio of MPTP-injected over control side (right over
left) to account for global inter-subject variation. Results were analyzed with Matlab (Natick,
Diffusion tensor imaging measures of nigrostriatal neurons
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MA). Linear regression was performed between the DTI parameters and the PET and histolog-
ical data obtained in each macaque.
Results
All the results plotted below are ratios of the value in the right lesioned side divided by the con-
trol left side. The only exceptions to this are the parkinsonism motor ratings and the MPTP
dose.
Fig 1. Nigrostriatal track volume. T2 weighted coronal image through the striatum (A) and FA weighted image (B) with superposed nigrostriatal track volumes (right
in orange and left in blue) in a single monkey. Analogous transverse images at a level above the substantia nigra are shown in (C) and (D).
https://doi.org/10.1371/journal.pone.0202201.g001
Diffusion tensor imaging measures of nigrostriatal neurons
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Results of the MD in the nigrostriatal tract
MPTP dose correlated with diffusivity parameters in the nigrostriatal tract (Fig 2). Monkeys
with nigral cell body loss of less than 50% are represented with crosses, and monkeys with
greater than 50% cell loss with circles. This convention is kept in the subsequent figures. There
was no correlation of MPTP dose with FA values. Note that the larger MPTP doses correspond
to increased mean diffusivity (MD) values on the affected side as compared to the control side.
In the following analyses, diffusivity measures constitute the primary DTI results.
The in vivo MD measures in the nigrostriatal tract correlated with the in vitro unbiased
stereologic counts of TH-stained nigral cell count and the striatal fiber density (measured by
stereology of TH-stained fibers) (Fig 3). The increase in MD in the nigrostriatal tract contin-
ued to increase throughout the range of either nigral cell loss (reflecting cell bodies in the
Fig 2. Diffusivity measures correlated with MPTP dose. Diffusivity ratios (dimensionless, affected side divided by normal side) correlated with MPTP dose (mg/kg
body weight). The diffusivity measures include (A) Mean diffusivity (R2 = 0.33, p = 0.02), (B) Radial diffusivity (R2 = 0.31, p = 0.02), and (C) Axial diffusivity
(R2 = 0.32, p = 0.02). Crosses indicate monkeys in which there was less than 50% loss of nigral cell bodies, and circles indicate monkeys in which there was a greater
than 50% loss of nigral cell bodies.
https://doi.org/10.1371/journal.pone.0202201.g002
Fig 3. Nigral cell count and striatal fiber length density as a function of MD in the nigrostriatal tract. (A) Nigral cell count as a function of the MD in the
nigrostriatal tract (R2 = 0.28, p = 0.03). (B) Striatal fiber length density as a function of the MD in the nigrostriatal tract (R2 = 0.29, p = 0.04). Crosses indicate monkeys
in which there was less than 50% loss of nigral cell bodies, and circles indicate monkeys in which there was a greater than 50% loss of nigral cell bodies.
https://doi.org/10.1371/journal.pone.0202201.g003
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substantia nigra, Fig 3A) or striatal fiber density (reflecting nigrostriatal tract fibers throughout
the striatum, Fig 3B).
In contrast, in vivo MD measures in the nigrostriatal tract did not clearly correlate with in
vitro histological measures of terminal fields of nigrostriatal neurons in the striatum. Once the
loss of nigral cells bodies exceeded 50% (cross signs in Fig 4), the in vitro histological terminal
field measures reached a floor while the MD measures continued to increase. These in vitro
measures include HPLC-based quantification of striatal dopamine concentration (Fig 4A), ste-
reological-based measures of DAT varicosity density (Fig 4B) and the average terminal arbor
density measures (Fig 4C). These plots demonstrate that, when the MD values on the affected
side exceed those on the control side by greater than 10% (MD>1.1 on the x-axis of the plots),
the striatal dopamine measures reach a maximal reduction (floor effect).
In vivo MD measures in the nigrostriatal tract have the same relationship to in vivo PET
measures of presynaptic markers as they do to in vitro histologic measures of terminal fields
(Fig 5). In this case, the MD measures increased as the in vivo terminal field measures initially
declined. However, once the striatal PET measures reached near zero (again corresponding to
about a 50% loss of nigral cell bodies), the MD measures continued to increase despite no fur-
ther change in the striatal PET measures. Striatal CFT (a DAT marker, Fig 5A), DTBZ (a
Fig 4. Histological measures of terminal fields of nigrostriatal neurons in the striatum as a function of the MD in the nigrostriatal tract. The measures include
(A) HPLC quantification of striatal dopamine measures, (B) Stereological measure of DAT varicosity density, (C) Average terminal arbor density. Crosses indicate
monkeys in which there was less than 50% loss of nigral cell bodies, and circles indicate monkeys in which there was a greater than 50% loss of nigral cell bodies.
https://doi.org/10.1371/journal.pone.0202201.g004
Fig 5. In-vivo PET measures of pre-synaptic markers as a function of the MD in the nigrostriatal tract. The measures include (A) Striatal CFT (a DAT marker),
(B) DTBZ (a VMAT2 marker), (C) FD (a decarboxylase marker). Crosses indicate monkey’s in which there was less than 50% loss of nigral cell bodies, and circles
indicate monkeys in which there was a greater than 50% loss of nigral cell bodies.
https://doi.org/10.1371/journal.pone.0202201.g005
Diffusion tensor imaging measures of nigrostriatal neurons
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VMAT2 marker, Fig 5B) and FD (primary a decarboxylase marker, Fig 5C) changed in the
same fashion as shown in Fig 4.
Results of other DTI parameters in the nigrostriatal tract
The other diffusivity parameters in the nigrostriatal tract (AD and RD) demonstrated findings
similar to the MD. Thus, Fig 2B and 2C demonstrate statistically significant linear correlations
between the AD and RD and MPTP dose (p = 0.02 in both cases). Plots of AD and RD analo-
gous to Fig 3 also demonstrated statistically significant linear correlation between the AD and
RD and nigral cell counts as well as striatum fiber length density (p< = 0.04 in all cases) (S1
Fig). The floor effect was well visualized with these variables in plots analogous to Figs 4 and 5
(S2 and S3 Figs). There was no consistent relation between the FA measure and the diffusivity
measures and no FA floor effect.
Results of DTI parameters in the regions of the SN and striatum
In addition to the above reported analysis in the nigrostriatal tracts, we repeated this analysis
for the end points of the tracts, selecting ROIs in the SN and the striatum. No statistically sig-
nificant effects were noted in any of the DTI measurements in the SN and striatum ROIs. A
weaker floor effect was noted in these areas in the diffusivity measures (MD, RD, and AD).
Measures of MD in the nigrostriatal tract did not correlate with motor ratings of parkinson-
ism. The ratings used were those that most closely corresponded in time with the MRI-based
DTI measures and not those previously published [6].
Discussion
We report that MD measures in the nigrostriatal tract of non-human primates exposed to
MPTP correlate with the degree of in vitro measures of nigral cell body injury or distal striatal
fiber length density. Numerous prior studies have demonstrated the underlying microscopic
basis for the diffusion tensor signal and the ability to infer microstructural information from
DTI data [1]. In our data, MD measures of the nigrostriatal tract correlated throughout the
range of deficits with nigral cell bodies and striatal fiber length density (Fig 3). Thus, MD mea-
sured in the nigrostriatal tract likely reflects the integrity of nigrostriatal cell bodies and axons
(measures located in the left column, Table 1). These results provide direct validation of in vivo
MRI-based MD diffusivity measures of the nigrostriatal tract.
The in vivo MRI-based MD measures do not correlate with the striatal terminal field mea-
sures (measures located in the right column, Table 1), whether obtained in vivo with PET radi-
oligands targeting presynpatic nigrostriatal neurons (Fig 5) or in vitro measures of striatal
terminal fields (Fig 4). With greater nigral cell loss, the DTI based MD measures of the nigros-
triatal tract continue to increase despite the lack of change in the near zero striatal values of the
in vitro and in vivo striatal terminal field measures. This rather marked distinction supports
the notion that the nigral cell bodies and striatal fiber length density measures change together
with injury of the nigrostriatal tract whereas the terminal field measures of the nigrostriatal
tracts reach a floor with respect to cell body and fiber density measures. We reported this same
floor effect comparing in vitro histological data with striatal dopamine and the nigral cell
counts as well as between in vivo PET measures of terminal fields with CFT, DTBZ or FD com-
pared to nigral cell counts [3]. Our data provide no evidence that MD measures in the nigros-
triatal tract reflect terminal field measures, whether measured by in vitro or in vivo methods.
There was no evidence of a floor effect with respect to motor parkinsonism and measures
of nigral cell count or striatal fiber length density. One might anticipate that the in vivo MD
measures would correlate with the in vitro striatal fiber length density measures since both
Diffusion tensor imaging measures of nigrostriatal neurons
PLOS ONE | https://doi.org/10.1371/journal.pone.0202201 September 5, 2018 9 / 14
reflect the fibers connecting nigral cell bodies and striatal terminal fields. Indeed, we did find a
moderate correlation between the MD measures and the striatal fiber length density (Fig 3B).
The in vivo DTI measures were derived from neuroimaging measures between the substantia
nigra and striatum, whereas, the in vitro striatal fiber density measures included data only
from TH fibers in the striatum. The degree of loss in these two locations and the potential dif-
ferences in sensitivity of these two measures could contribute to some variability. In fact,
degeneration of the nigrostriatal tract may occur through axonal degeneration in PD [18, 19]
and may be even more likely in MPTP-induced injury since MPTP gains entry to dopaminer-
gic cells through DAT [20]. A similar analysis applies to comparison of the MD measures in
the nigrostriatal tract with in vitro stereologic measures of TH stained cell bodies in the sub-
stantia nigra (Fig 3A). The relatively stronger correlation between MPTP dose and the in vivo
MD measures in the nigrostriatal tract (Fig 2) probably reflects the general degree of injury
produced by MPTP that may occur throughout the nigrostriatal pathway. The lack of correla-
tion between the DTI measures and severity of parkinsonism may reflect time-dependent
degeneration not accounted for in the acquired MRI data. We previously reported that behav-
ioral measures correlate well with nigral cell counts of TH-stained neurons when collected at
nearly the same time, two months after MPTP [6]. At this time, all behavioral measures were
quite stable; our preliminary data suggest that this is when the in vitro measures also are stable.
In contrast, in the current study, these in vitro and behavioral measures were collected at dif-
ferent times.
Ex-vivo histological correlation with DTI values has been demonstrated in various models
of neuronal fiber tissue, including demyelinating and dysmyelinating disease [21], models of
traumatic brain injury in mice [22], spinal cord lesions in humans [23], and in multiple other
animal models, although, to our knowledge, such comparisons have not been done for the
nigrostriatal tract, an area with potentially confounding crossing fibers, and an area that is par-
ticularly pertinent to progression of PD.
Our study has relevance to investigations in people with PD. Degeneration of the nigros-
triatal tract contributes to motor manifestations in animal models of PD [6] and to people
with PD [19, 24]. Thus, DTI potentially provides an in vivo MRI-based method for identifying
early degeneration that may occur in PD. The sensitivity and specificity of this approach
remain to be determined. A study by Ofori et al. [25] used a novel bi-tensor diffusion model to
evaluate the free water content in the substantia nigra in a group of 25 patients with PD and a
control group. These subjects were followed over a 1 year period. Free water values were found
to be stable in the control group but increase in the PD group and also predict changes in bra-
dykinesia scores and cognitive status. These findings were further confirmed in a larger multi-
site cohort that was followed over a 4 year period [26]. These results are consistent with our
study since both the MD (average diffusion in the voxel) and free water (a measure of the
extracellular isotropic volume fraction) are related measures, although free water content is a
more sensitive measure. Meijer et al. [27] recently reviewed prior cross-sectional studies of PD
with DTI used various forms. Some of the reviewed studies reported decreases in FA [28–30]
(not seen in our study), and all but one reported increased diffusivity in PD [29] (similar to
our findings), although direct comparison with our results is difficult due to differences in
methodology. All of these reviewed studies compared patients with PD (and often some atypi-
cal variants) vs. a healthy control group, which experimental design differs from that used in
our MPTP study. A more recent study by Tan et al. [31] compared DTI values in the nigros-
triatal tract in 21 patients with PD with those in 19 healthy controls using deterministic tracto-
graphy. This methodology is similar but not identical to our use of probabilistic tractography.
They demonstrated significant differences in DTI parameter values in the nigrostriatal tract
including lower FA (not seen in our study) and higher diffusivity values in the MD and RD,
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but not AD. Our study demonstrated higher diffusivity in all diffusivity measures. The discrep-
ancy in the FA values between our study (no change) and the decrease in FA reported in Tan
et al. and other studies may relate to the difference between human PD and the focal, MPTP
induced PD symptoms measured in our study. Another possible reason for these discrepancies
in the PD literature is that changes in the free water extracellular compartment in SN found
using a bi-tensor model are confounded using a standard DTI analysis[32]. It is possible that
our positive results reflect use of probabilistic tractography which involves a more complicated
algorithm than the standard single tensor model [16].
DTI of the nigrostriatal tract potentially provides an objective measure of severity of nigros-
triatal injury. This technique could help to assess efficacy of new therapies, particularly in early
PD. Routine clinical application may or may not be feasible. The relationship of the MD mea-
sures in the nigrostriatal tract with nigral cell counts suggests that this measure also may reflect
the full range of nigrostriatal injury, a major advantage compared to molecular imaging meth-
ods focused on presynaptic measures in the striatum [3]. Although some MR-based measures,
like the bi-tensor model, are not changed by drugs used for symptomatic treatment [33] this
remains to be proven for our method. Longitudinal measures in people with PD will be needed
to determine whether our methods reflect disease progression, as others have done for bi-ten-
sor measures in SN [26]. Further studies will be required to fully evaluate this method in
human populations.
Supporting information
S1 Fig. Nigral cell count and striatal fiber length density as a function of RD and AD in the
nigrostriatal tract. (A,C) Nigral cell count as a function of the RD and AD in the nigrostriatal
tract. (B,D) Striatal fiber length density as a function of the RD and AD in the nigrostriatal
tract (R2 = 0.29, p = 0.04). Crosses indicate monkeys in which there was less than 50% loss of
nigral cell bodies, and circles indicate monkeys in which there was a greater than 50% loss of
nigral cell bodies.
(TIF)
S2 Fig. Histological measures of terminal fields of nigrostriatal neurons in the striatum as
a function of the RD and AD in the nigrostriatal tract. The measures include (A,D) HPLC
quantification of striatal dopamine measures, (B,E) Stereological measure of DAT varicosity
density, (C,F) Average terminal arbor density. Crosses indicate monkeys in which there was
less than 50% loss of nigral cell bodies, and circles indicate monkeys in which there was a
greater than 50% loss of nigral cell bodies.
(TIF)
S3 Fig. In-vivo PET measures of pre-synaptic markers as a function of the RD and AD in
the nigrostriatal tract. The measures include (A,D) Striatal CFT (a DAT marker), (B,E)
DTBZ (a VMAT2 marker), (C,F) FD (a decarboxylase marker). Crosses indicate monkey’s in
which there was less than 50% loss of nigral cell bodies, and circles indicate monkeys in which
there was a greater than 50% loss of nigral cell bodies.
(TIF)
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